Protecting the Aging Retina by Nian, Shen & Lo, Amy C.Y.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Protecting the Aging Retina
Shen Nian and Amy C.Y. Lo
Abstract
Aging retina, notably the aging macula, is prone to develop degenerative 
diseases, such as age-related macular degeneration (AMD), the leading cause of 
visual loss in individuals aged 65 or above in developed countries. However, current 
treatments are very limited. Since degeneration, dysfunction, and death of retinal 
neurons are demonstrated in the pathogenesis of AMD, neuroprotective strategies 
could serve as a possible way to treat AMD. In this chapter, we will briefly introduce 
risk factors, pathophysiology, affected neurons, classification, clinical manifesta-
tion, and current treatments of AMD. Finally, neuroprotection in both AMD animal 
models and patients will be discussed.
Keywords: neuroprotection, degeneration, photoreceptor, age-related macular 
degeneration, vision loss
1. Introduction
Retina, which forms the innermost layer of the eyeball, is considered as the end 
organ of the central nervous system. Macula, located in the central and posterior 
part of retina, possesses the highest concentration of photoreceptors and, therefore, 
is responsible for central vision and high-resolution visual acuity (VA). The fovea 
is a tiny pit in the center of the macula and in charge of the central, sharpest vision. 
Unfortunately, the macula is more prone to experience degenerative changes with 
age, such as age-related macular degeneration (AMD), leading to visual impairment.
Due to the increase of life expectancy worldwide, the size of aging population 
will become larger in the coming decades [1]. According to “World Population 
Prospects: The 2017 Revision” released by the United Nations, the number of per-
sons aged 60 or above will more than double, from 962 million in 2017 to 2.1 billion 
by 2050. The number of people aged 80 or above is predicted to triple by 2050, from 
137 million in 2017 to 425 million by 2050 [2]. In mainland of China, people aged 
above 65 represented 11.4% of the total population in 2017 [3]. As a consequence, 
the increasing prevalence of AMD will be foreseen globally in the future.
In 2015, it was estimated that AMD was the fourth leading cause of blindness 
and the third most common cause of moderate to severe visual impairment globally 
[4]. The meta-analysis performed by Wong and collaborators has estimated that 
the number of persons with AMD will increase from 196 million in 2020 to 288 
million in 2040 worldwide [5]. A similar trend is observed in the projected number 
of individuals affected by AMD in China, rising from 31.23 million in 2020 to 55.19 
million in 2050 [6]. In addition, the prevalence of late AMD did not show signifi-
cant difference among Asian, European, and North American studies, whereas the 
number of individuals with early AMD was more in European and North American 
studies than in Asian studies [7].
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2. Anatomy and function of the retina
The eye is composed of three layers, which are the inner retina layer, middle 
vascular choroid layer, and outer fibrous sclera layer, respectively. Retina, the inner-
most layer of the eye, consists of two parts: the inner transparent neurosensory 
retina and outer pigmented epithelial layer—the retinal pigment epithelium (RPE). 
There is a potential space between neural retina and RPE, called subretinal space. 
In the neural retina, the neural cell bodies are situated in three layers (Figure 1), 
including the outer nuclear layer (ONL) occupied with nuclei of photoreceptors; 
the inner nuclear layer (INL) filled with nuclei of horizontal, bipolar, and most of 
the amacrine cells; as well as ganglion cell layer (GCL) containing nuclei of retinal 
ganglion cells and the rest of displaced amacrine cells. Additionally, axons and den-
drites of these retinal neurons constitute two synaptic layers: the inner plexiform 
layer (IPL) and outer plexiform layer (OPL) [8]. The RPE cells form a continuous 
polarized cell monolayer with its apical surface adjacent to the outer segment apices 
of the photoreceptors and its basal aspect lying on supportive substrate Bruch’s 
membrane.
Retinal neurons are mainly distributed in three layers: ONL with nuclei of 
photoreceptors; INL with nuclei of horizontal, bipolar, and most of the amacrine 
cells; and GCL with nuclei of retinal ganglion cells and the rest of displaced ama-
crine cells. Additionally, axons and dendrites of these retinal neurons constitute two 
synaptic layers, including IPL and OPL [8].
Photoreceptors are divided into two types: rods, which are dominated in the 
peripheral retina and responsible for dim light vision and detecting movement 
and contrast, and cones, which are dominated in the macula, especially the fovea 
(only cones), and are responsible for bright light vision and sensing color vision 
Figure 1. 
Retinal layers of the human eye.
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and resolution. Outer segments of the photoreceptor are generated by the cell body, 
and the distal parts of outer segments are phagocytosed by RPE every day. There 
are abundant mitochondria in inner segments to supply energy for these cells with 
high metabolic rate. Bruch’s membrane, where the RPE cells are tightly attached, 
consists of five layers including, from inner to outer, the RPE basal lamina, inner 
collagenous zone, elastic layer, outer collagenous zone, and basement membrane of 
the choriocapillaris [9].
In brief, the function of the retina is to convert the external light signals into 
electrical impulses by photoreceptors. The impulses, which are partly integrated 
locally by horizontal cells and amacrine cells, are then processed by bipolar cells 
and sent to ganglion cells which further transmit them to the brain. Moreover, 
RPE is crucial for maintaining the microenvironment of neural retina by exchang-
ing nutrients and wastes between neural retina and choroid, secreting numerous 
growth factors, phagocytosing shed photoreceptor outer segments (POS), absorb-
ing light and converting all-trans-retinal into 11-cis-retinal [10]. Any defects in any 
of these functions may result in retinal degeneration, deficits of visual function, 
and eventually loss of sight.
3. Current knowledge of AMD
3.1 Classification and clinical manifestations
A variety of classification systems are employed for both clinical and basic 
research of AMD. However, the most commonly used classification is the one 
defined by the Age-Related Eye Disease Study (AREDS) in terms of the characteris-
tics of drusen (yellow deposits in the macula), abnormal hypo- or hyperpigmenta-
tion in the first eye, and how it affected the fellow eye. Based on the above criteria, 
AMD is classified into 4 categories: (1) no clinical manifestation of AMD if there 
was no drusen or only non-extensive, small drusen (<63 μm in diameter) in both 
eyes; (2) mild AMD classified by extensive small drusen, non-extensive intermedi-
ate drusen (63–124 μm in diameter), or abnormalities of pigments in at least one 
eye; (3) intermediate AMD characterized with large drusen (>124 μm in diameter), 
extensive intermediate drusen, or noncentral geographic atrophy (GA) in at least 
one eye; (4) advanced AMD defined as central GA or choroidal neovascularization 
(CNV) resulting in VA less than 20/32 [11–13].
There are two clinical types of advanced AMD: a non-exudative or atrophic 
(dry) form, accounting for 90% of AMD, and an exudative (wet) form, accounting 
for only 10% of AMD. The atrophic form is characterized by progressive degen-
eration of RPE cells and photoreceptors in the macula, affecting central vision to 
varying degrees over months or years [14, 15]. The exudative form is associated with 
CNV in the submacular area and subsequent retinal hemorrhage due to leakage of 
these newly formed fragile blood vessels, leading to severe central vision loss within 
a very short period of time [15].
At the early stage of AMD, patients are normally asymptomatic and may be diag-
nosed by the presence of round, yellowish drusen through the routine ophthalmo-
logical examinations. Patients with CNV usually suffer from sudden loss of vision, 
describing unexpected deterioration of central visual field, distorted straight line 
(metamorphopsia), and/or a dark area in the central visual field (scotoma). On 
fundus examination, macular edema and hemorrhage are observed and fluorescein 
angiography shows leakage. In non-exudative AMD, it takes years for patients to 
develop visual loss gradually, and fundus examination shows a well-defined RPE 
atrophic area with depigmentation (Figure 2) [15].
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3.2 Risk factors
A number of risk factors are thought to be related to the pathogenesis of AMD, 
such as increasing age, smoking, family history of AMD, overweight or obesity, 
cataract and cataract surgery, eye exposure to the sunlight, etc. Of these factors, age 
is the strongest risk factor, with around 30% of cases older than 85 years diagnosed 
with AMD in US [17, 18]. The risk of developing AMD was reported to be more than 
triple in patients above 75 years than patients aged between 65 and 74 years [18, 19]. 
In populations of European ancestry, the projected prevalence of late AMD was 
0.08% at age 50, 0.33% at age 60, 1.38% at age 70, 5.60% at age 80, and 20.10% at 
age 90, respectively [20]. Similarly, the estimated prevalence of any AMD increased 
from 2.44% in persons at the age of 45–49 years to 18.98% in persons at the age of 
85–89 years [6].
Ethnicity and family history are also strongly related with AMD prevalence. The 
highest rate was reported in Caucasians, followed by Hispanics and Asians, while 
African Americans showed the lowest morbidity rate [21]. Increased risk of AMD 
was observed in individuals with positive family history, approximately three to six 
times higher than it was for those from the general population [22]. Furthermore, 
genetic studies have revealed 34 loci linked to AMD until now, of which comple-
ment factor H (CFH) on 1q31.3, age-related maculopathy susceptibility 2 (ARMS2) 
on 10q26, and CFB/C2 on 6q21.3 were the most discussed genes [15, 23, 24].
The strong relationship between cigarette smoking and development of AMD 
has been widely accepted [17, 25, 26]. Several studies revealed that current smoking 
was strongly associated with the progression of AMD [27]. Moreover, past smoking 
was reported to be a risk factor to develop AMD as well, especially in the rural areas 
[28]. There was an increased risk for individuals with high intake of several types of 
fat, such as omega-6 polyunsaturated fatty acids and saturated fats, whereas diets 
rich in monounsaturated fatty acids might reduce the prevalence of AMD [29]. 
Inadequate uptake of antioxidants also resulted in AMD, and numerous studies have 
suggested that antioxidant supplementation, including vitamins, lutein, zeaxan-
thin, beta-carotene, zinc, etc., helped to halt the progression of AMD to some 
extent [12, 30, 31].
The effects of sunlight exposure on the occurrence of AMD are controversial. A 
study performed by Khan and colleagues demonstrated that no significant associa-
tion between light exposure and AMD was observed when comparing patients at 
the end stage of AMD with spouse controls [32]. However, other studies suggested 
that damages induced by either ultraviolet (UV) or visible sunlight might lead to 
Figure 2. 
Representative fundus of AMD patients. (A) Non-exudative form of AMD with a well-defined atrophic 
region and (B) exudative form of AMD with retinal hemorrhage and macula edema [16].
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AMD [33–35]. There was conflicting evidence regarding the role of cataract surgery 
in the progression of AMD [36]. Earlier, a large population-based research indicated 
a stronger relationship between cataract surgery with the development of end-stage 
AMD, especially neovascular AMD, in older patients [36, 37]. On the contrary, 
several recent clinical studies failed to demonstrate similar results [36, 38].
In addition to the risk factors mentioned above, other relevant factors included 
hypertension, cardiovascular diseases, iris color, hyperlipidemia, diabetes, alcohol 
consumption, and so on [22]. According to a systematic review of 18 prospective 
and cross-sectional studies and 6 case-control studies engaging 113,780 individuals, 
advancing age, cigarette smoking, previous cataract surgery, and family history 
of AMD were considered as the strong risk factors of AMD, while hypertension, 
cardiovascular disease, overweight or obesity, and elevated plasma fibrinogen were 
regarded as the moderate risk factors [17].
3.3 Pathophysiology
AMD is regarded as a complicated multifactorial disease, although the exact 
pathogenesis still remains poorly understood. It is generally recognized that impair-
ment of aged RPE cell functions served an important role in the progression of 
non-exudative AMD. The aged RPE cells were less efficient in phagocytosing and 
degrading POS, resulting in the progressive accumulation of lipofuscin consisting 
of phagosomal and lysosomal constituents in the cytoplasm. The cytotoxic elements 
in lipofuscin, such as bisretinoid fluorophore, were able to generate reactive oxygen 
species leading to the damage of DNA, lipids, and proteins [39].
Another age-dependent change was the formation of focal extracellular yellow 
deposits known as drusen, the hallmark of AMD, between the RPE and Bruch’s 
membrane. Accumulation of drusen relied on the changes in the permeability of 
Bruch’s membrane due to the decline of RPE cell functions with aging [40]. In 
addition, it has been estimated that breakdown of choriocapillaris, which was next 
to RPE and Bruch’s membrane, resulted in insufficient elimination of extracel-
lular wastes causing drusen [41]. According to their shape and size, drusen are 
separated into small (<125 μm), round hard drusen with well-defined borders, and 
relatively large, (125–250 μm) soft drusen with poorly defined borders. Soft drusen, 
especially with depigmentation or pigment abnormalities, was considered to be an 
indication to give rise to severe vision loss at the late stage.
The mechanism of drusen causing adjacent RPE and photoreceptors’ damage 
was not only dependent on the structural disturbance of RPE and photoreceptor by 
them, but also on the indirect effects through stimulation of local inflammation and 
immune system [42, 43]. Components in complement pathway and inflammatory 
processes were observed in drusen and aged RPE cells that are closely related to 
drusen [42]. It was demonstrated that in AMD, genetic variation of factor H gene 
(HF1/CFH) induced the abnormal activities of factor H (the inhibitor of comple-
ment cascade) in drusen, leading to the activation of complement pathway and 
subsequent inflammation in subretinal tissues [44]. Furthermore, in AMD patients, 
decreased CFH level was reported in smokers than nonsmokers, suggesting the 
activation of complement cascade might contribute to the significantly higher risk 
of AMD progression in cases with smoking [45].
DICER1, the ribonucleic acid (RNA)-cleaving enzyme, was decreased in RPE 
cells in cases with non-exudative AMD. A group of researchers in the University 
of Kentucky suggested that the lower level of DICER1 led to the lower rate of Alu 
RNA degradation in RPE cells. Therefore, accumulation of Alu RNA in cytoplasm 
resulted in RPE cytotoxicity and consequent degeneration via activating NLRP3 
inflammasome [46, 47].
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In exudative AMD, local nonspecific inflammation stimulated the upregulation 
of angiogenic factors, such as vascular endothelial growth factor (VEGF), and/or 
downregulation of anti-angiogenic factors, such as pigment epithelium-derived fac-
tor (PEDF), causing CNV development in the avascular outer 1/3 retina. The new 
vessels are fragile, thus macular edema and hemorrhage occur due to the leakage 
of these new blood vessels, which finally resulted in the fibrovascular scars in the 
macula [41, 48].
3.4 Affected neurons
Due to the dysfunction of aged RPE cells, especially the failure of POS phago-
cytosis, photoreceptor loss occurs subsequently. Although the most remarkable 
clinical and pathological injuries are present in RPE and its underlying Bruch’s 
membrane, it is the structural and functional disruptions, even the death of 
photoreceptors, via either atrophic or neovascular process, that take responsibilities 
for the visual impairment in AMD. Furthermore, the condition of photoreceptors 
directly reflects the significance of lesions in RPE/Bruch’s membrane complex.
It is crucial to identify which type of photoreceptors are most severely damaged 
in AMD, not only for the potential therapeutic strategies targeting the most affected 
cells, but also for investigation of mechanism of these pathological changes. The 
rate of rod and cone degeneration is representative in different situations affecting 
photoreceptors. In aging retina without age-related maculopathy, the number of 
cells in the cone-dominated fovea remained stable, while the number of rods in the 
parafovea was reduced by 30% [49]. In both non-exudative and exudative forms of 
AMD, photoreceptors were lost. In addition, more rod loss was observed than that 
of cones; gradually, only degenerated cones were left; finally, all photoreceptors 
might die [50]. The pathological changes mentioned above were consistent with the 
functional research exhibiting that scotopic sensitivity decreased more than phot-
opic sensitivity in cases with AMD [51]. Maeda and colleagues revealed the apopto-
sis of photoreceptors after RPE damage caused by intravitreal injection of ornithine 
in rats, indicating the important role of RPE cells in maintaining photoreceptor 
integrity [52]. In AMD patients, apoptotic photoreceptors and RPE cells (TUNEL 
positive) were observed as well. Most of TUNEL-positive photoreceptors were rods 
and located at the edge of RPE atrophy. Moreover, Fas was upregulated in apoptotic 
photoreceptors, indicating Fas/FasL might be involved in the apoptosis process [53]. 
Studies performed by Kim and collaborators demonstrated that significant reduc-
tion of photoreceptors was shown in the areas where RPE cells were totally lost in 
GA, and where disciform scar formed in wet AMD [54, 55]. In terms of disciform 
scar, thickness of the scar was closely associated with photoreceptor loss, which 
means that the thicker the disciform scar, the less photoreceptors survived [56].
In addition to photoreceptors, other retinal neurons are also affected. Joshua 
et al. first reported that TUNEL-positive cells were detected in the inner side of 
INL, indicating that these cells might be amacrine cells [53]. In cases with GA, 
retinal ganglion cells were significantly decreased by 30.7% compared to age-
matched control. However, cell nuclei in INL were not significantly different [54]. 
In wet form of AMD, a decrease of ganglion cells and increase of cells in INL were 
observed, but there was no significant difference [55].
3.5 Current treatments
Several treatments have been adopted for AMD management. However, current 
therapeutics can only slow the progression of the disease, trying to delay the onset 
of vision loss as much as possible.
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To date, there are no approved drugs for the dry form of AMD. Therefore, 
much effort has been made to reduce risk factors. Among various risk factors, 
oxidative stress induced by inflammation, light exposure, and so on is considered 
as one of the most important risk factors for the occurrence and progression of 
AMD. Numerous studies have been conducted to evaluate the relationship between 
antioxidant nutrition supplementation and AMD. In the Age-Related Eye Disease 
Study (AREDS), it was demonstrated that oral dietary supplementation containing 
vitamin C (500 mg/day) and E (400 IU/day), zinc oxide (80 mg/day), cupric oxide 
(2 mg/day), and beta-carotene (15 mg/day) can decrease the risk of development 
of AMD from intermediate stage to advanced stage [11]. Since beta-carotene was 
observed to increase the risk of lung cancer in cigarette smokers, and 80 mg/day 
zinc is out of tolerance for individuals, there were elimination of beta-carotene, 
decreased dose of zinc (25 mg/day), and adding of lutein and zeaxanthin in the 
AREDS2 formula [12, 57, 58]. A 10% reduction in developing to advanced AMD was 
present in patients treated with AREDS2 formula containing lutein and zeaxanthin 
[59]. In addition, healthy diet rich in fish, green leafy vegetables, and nuts together 
with healthy lifestyle are strongly recommended to reduce AMD risk factors [15].
For the wet form of AMD, therapies mainly focus on halting the progression of 
CNV. Thermal laser photocoagulation is the first treatment to stop the progression 
of CNV successfully, but with no significant vision improvement and high recur-
rence of CNV. Photodynamic therapy with verteporfin can selectively damage the 
CNV tissue without additional injuries of neighboring tissue, but this therapy has 
no effects on visual improvement either. In terms of upregulation of VEGF in the 
development of CNV, intravitreal injection of anti-VEGF drugs has been widely 
used by ophthalmologists as a standard treatment. Anti-VEGF drugs (Pegaptanib 
sodium, Ranibizumab, and Bevacizumab) for exudative AMD have demonstrated 
exciting results: the vision in the majority of patients remained stable for 1 year, of 
which 40% of patients had visual improvement. Surgical intervention to remove 
CNV and submacular hemorrhage did not improve VA, which is the result of recur-
rence of CNV [15, 60].
4.  Neuroprotection in AMD experimental studies and clinical 
approaches
Neuroprotection comprises a large number of therapeutic interventions to 
improve survival of neurons by modifying the structure and function of neurons, 
and/or their microenvironment. Initially, neuroprotective therapies are focused on 
central nervous system diseases including stroke, Alzheimer’s disease, Parkinson’s 
disease, etc. Since retina is regarded as the end part of central nervous system, 
a series of neuroprotective strategies has been applied to prevent vision loss by 
protecting retinal neurons. Furthermore, tremendous neuroprotective strategies are 
under investigation in both experimental and clinical research.
4.1 Studies in animal models
Neurotrophic factors, belonging to the family of growth factors, have the 
ability to promote survival of retinal neurons. Ciliary neurotrophic factor (CNTF) 
is one of the most extensively studied neurotrophic factors for neural retina 
protection. La Vail and collaborators first reported that intraocular injection of 
CNTF obviously prevented photoreceptor death from light-induced damage in 
Sprague Dawley rats [61]. Subsequently, intravitreal injection of adenoviral vec-
tor containing CNTF cDNA in rd1 mice, a naturally occurring mouse model for 
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retinal degenerative diseases, demonstrated the reduction of photoreceptor loss, 
conservation of ONL thickness, and increase of photoreceptor segments’ length. 
Moreover, the amplitudes of a-wave and b-wave in electroretinogram (ERG) were 
significantly increased compared with those of the control group, suggesting the 
preservation of retinal functions [62, 63]. Later, long-term protective effects of 
photoreceptors were shown using adeno-associated virus to deliver CNTF to the 
retina [64]. In order to sustainably deliver neurotrophic factors, encapsulated 
human RPE cells secreting CNTF were transplanted into the vitreous of rcd1 dog 
(a dog model of retinal degeneration). A significant increase of ONL thickness was 
observed in the treated eye as a result of continuous release of CNTF at the nano-
gram level [65]. No adverse effects were exhibited in the retina of transplanted eyes 
during the whole experiment period (7 weeks). In addition, CNTF was proved to 
protect loss of cone outer segments, an early sign of cone degeneration, indicating 
that CNTF could not only slow or halt progression of degeneration but also might 
reverse degeneration [66].
Placental growth factor (PIGF), one of the members of vascular endothelial 
growth factor family, was believed to prevent neuronal injury in the brain. In the 
retina, the role of PIGF was exhibited quite differently in in vitro and in vivo studies. 
Blue light-induced murine photoreceptor cell death was significantly attenu-
ated after the treatment of PIGF by suppressing caspase-3/7 activity through the 
mitogen-activated protein kinase (MEK) and phosphoinositide 3-kinase (PI3K) 
pathway. Anti-PIGF antibody eliminated these protective effects [67]. However, 
in the light-induced retina-damaged mouse model, PIGF induced decreased ONL 
thickness and dysfunction of retina. Anti-PIGF antibody diminished neuroretinal 
injury and disruption of RPE cell-cell junctions after exposure to the white light for 
3 h [68]. The opposite effects of PIGF and its antibody in mice were later found to 
be due to the hyperpermeability of RPE induced by PIGF, leading to the breakdown 
of retina-blood barrier and subsequent damages [68].
Ursodeoxycholic acid (UDCA) and its taurine-conjugated derivative taurourso-
deoxycholic acid (TUDCA) were first found in the bile acid of hibernating bears. 
They have been used for liver detoxification, dissolution of gallstone and kidney 
stone, suppression of convulsions, and visual improvement in traditional Chinese 
medicine for a very long time. According to the theory of modern medicine, UDCA 
and TUDCA exhibit neuroprotective effects through prevention of cell apoptosis 
[69]. TUDCA treatment significantly preserved the number and structure of 
photoreceptors and retinal functions in different murine models of photoreceptor 
degeneration, including rd10 mice, rd1 mice, BALB/c mice, Bardet-Biedl syndrome 
type 1 mice, and transgenic P23H rats [69]. Furthermore, TUDCA manifested 
greater protective effects in cones [70]. In vitro studies using photoreceptor 661 W 
cells revealed that reduced endoplasmic reticulum (ER) stress and improved traf-
ficking of cyclic nucleotide-gated channels in cones contributed to neuroprotective 
effects of TUDCA [71]. In addition, TUDCA improved phagocytosis of POS in 
H2O2-treated RPE cells via activating Mer tyrosine kinase receptor (MerTK), which 
indirectly protected photoreceptors [72].
Endogenous and exogenous progesterone have been certified to have neuro-
protective effects in brain and retina for several decades. A broad range of studies 
have been conducted in either light-damaged or genetic murine models of retinal 
degeneration, demonstrating improvement in photoreceptor survival, decreased 
gliosis, and reduced retinal dysfunction after administration of progesterone or 
synthetic progestins [69]. A group of researchers in Spain revealed that rd1 mice 
orally administered with progesterone (100 mg/kg body weight) at postnatal 
day 7 (P7) exhibited significantly decreased number of apoptotic cells in ONL in 
the far peripheral retina and increased amplitude of ERG b-wave at P15, but no 
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significant change was observed at P17. There was also a transient reduced gliosis 
in the treated rd1 mice [73]. Similar results were observed with oral administration 
of synthetic progestin, known as the FDA-approved Norgestrel, showing reduction 
of photoreceptor death by 70 and 75% in light-damaged mouse model and rd10 
mice, respectively [74]. The rescue effects were achieved by increasing production 
of basic fibroblast growth factor and its downstream pro-survival reactive oxygen 
species [74, 75].
Crystallins, critical family members of small heat shock proteins, have been 
identified to have novel functions in both retina and RPE as in the lens, such as anti-
apoptosis and anti-inflammation. αB-Crystallin is secreted in exosomes released 
from apical surface of polarized RPE cells and accumulates in the matrix among 
photoreceptors, and therefore may protect neighboring RPE and photoreceptors 
[76]. RPE cells in αB-crystallin knockout mice exhibited high susceptibility to 
oxidative stress and endoplasmic reticulum stress compared to the RPE cells from 
wild-type mice. Furthermore, RPE cells overexpressing αB-crystallin were more 
resistant to apoptosis, indicating the protective effects of αB-crystallin [77]. In the 
mouse model of AMD induced by sodium iodate (NaIO3), absence of αB-crystallin 
accelerated RPE apoptosis with subsequent death of photoreceptors through 
upregulation of AKT phosphorylation and expression of peroxisome proliferator-
activator receptor-γ, suggesting αB-crystallin, especially the small peptide called 
mini cry, may play an important role in the protection of retinal degeneration [77]. 
In order to prolong the life of mini cry in the vitreous, free mini cry was fused to 
form an elastin-like polypeptide (ELP), which could be detected in the vitreous for 
up to 2 weeks. One intravitreal injection of ELP-linked peptide prevented RPE cells 
from apoptosis, inhibited activation of caspase-3 activation, and protected neural 
retina for up to 1 month after NaIO3 challenge [78].
NF-E2-related factor 2 (Nrf2) is a transcription factor that regulates antioxidant 
responses in many tissues and cell types, providing protection against oxidative 
stress. Under the oxidative stress, Nrf2 is translocated from cytoplasm to nucleus, 
and subsequently binds to the corresponding sites to activate transcription of a wide 
range of antioxidant genes. In the central nervous system, Nrf2 was proved to slow 
the neurodegeneration by means of antioxidative stress and neuroinflammation 
[79]. In the mice undergoing optic nerve crush (an animal model of glaucoma), 
retinal ganglion cells were significantly decreased than in the wild-type mice. 
With the treatment of Nrf2 activator, retinal ganglion cell loss was decreased by 
upregulating gene expression of antioxidant and phase II detoxifying enzymes [80]. 
After retinal ischemia-reperfusion injury, Nrf2 knockout mice showed greater loss 
of retinal ganglion cells when compared with the wild-type mice. Moreover, after 
ischemia-reperfusion injury, Nrf2 activator increased survival of retinal ganglion 
cells in wild-type mice, but not Nrf2 knockout mice, indicating the neuroprotective 
effects of Nrf2 [81]. An in vitro study has demonstrated that siRNA knockdown of 
Nrf2 led to significant increase of reactive oxygen species and cell death after blue 
light exposure in murine photoreceptor cells, suggesting that Nrf2 could be used to 
protect photoreceptors in AMD and other retinal degeneration [82].
There is no direct evidence that dopamine protects retinal neurons through anti-
inflammation, apoptosis, and oxidative stress. However, decreased expression of 
dopamine may play a negative role in neuron survival in the brain [83]. Thus, dopa-
mine receptor agonists may achieve the goal to promote retinal neuron survival and 
function by restoring the lost dopamine resulting from certain diseases. Dopamine 
receptor agonist pramipexole was shown to ameliorate structural and functional 
injuries in the light-damaged mice, exhibiting decreased photoreceptor death, 
damage of photoreceptor outer and inner segments, TUNEL-positive cells in ONL, 
and preservation of a-wave and b-wave in ERG [84]. Additionally, pramipexole 
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inhibited ARPE-19 cell (an immortalized RPE cell line) death after H2O2 treatment, 
suggesting its antioxidative effects [84].
Regular general physical exercise is not only a part of healthy life style, but also 
a rehabilitation strategy showing neuroprotective effects in numerous diseases. 
Recently, exercise has been proven to be neuroprotective in animal models of retinal 
degeneration [85–87]. Wild-type BALB/c mice were forced to exercise for 5 days/
week for 2 weeks before being exposed to bright light. Exercised mice showed 
greater improved amplitude of ERG b-wave and photoreceptor nuclei than the 
mice without exercise after light exposure [85]. In order to exclude the impact of 
stress caused by forced exercise, voluntary wheel running was adopted in rd10 
mice, which also demonstrated protection of VA, and the number of cones and total 
photoreceptors [86]. No matter if it was involuntary or voluntary exercise, either 
one benefited damaged photoreceptors in animal models of retinal degeneration 
through increased expression of brain-derived neurotrophic factor (BDNF) and 
activation of tropomyosin-related kinase B (TrkB) signaling pathway [85, 86].
Electrical neurostimulation has developed rapidly in recent years, covering 
a range of neurological diseases, such as neurostimulation for epilepsy, spinal 
cord stimulation for chronic pain, brain stimulation for Parkinson’s disease, and 
so on [88]. Electrical neurostimulation in vision research has also made a great 
improvement, from transcorneal, subretinal, to whole-eye electrical stimulation. 
Transcorneal electrical stimulation (TES) was performed in SD rats before or after 
exposure to the intense light for 14 days. Both the stimulation before and after light 
exposure slowed the progression of photoreceptor degeneration. Furthermore, 
TES after light exposure exhibited a longer and better protective effect. The neu-
roprotection effects may result from anti-apoptosis (upregulation of Bcl-2 and 
downregulation of Bax) and increased expression of neurotrophic factors (CNTF 
and BDNF) [89]. Subretinal electrical stimulation (SES) in the eye of Royal College 
of Surgeons (RCS) rats, a commonly used model of retinal degeneration, signifi-
cantly preserved amplitudes of b-wave and oscillatory potential, and implicit times 
of a-wave and b-wave, suggesting the preservation of not only photoreceptors, but 
also signal transmission in the retina [90]. Although the whole-eye electrical stimu-
lation did not provide protection for rod structure in P23H rats, b-wave amplitudes 
and rod sensitivity were significantly increased [91].
Although the neuroprotective strategies mentioned above have acquired promis-
ing results in animal models, damaged human retina can be only partially rescued. 
Miller and colleagues have investigated the underlying reasons using many animal 
models. There are three types of cell death including caspase-mediated apoptosis, 
autophagy-mediated cell death, and necrosis which is regulated by receptor-inter-
acting protein kinases (RIPK). In the animal model of retinal detachment, elevated 
expression and phosphorylation of RIPK together with activation of caspases were 
observed. When either RIPK or caspases were inhibited, no obvious rescue effects 
were demonstrated. However, inhibition of both RIPK and caspases resulted in 
significant protective effects. Similar results were found in the animal model of 
retinal degeneration which experienced both photoreceptor and RPE cell death. In 
this animal model, the dominant type of cell death in photoreceptors was apoptosis, 
while necrotic RPE cells were mainly exhibited. Therefore, therapies that block both 
RIPK and caspase pathways may provide more satisfactory neuroprotection [92].
4.2 Current medicine/neuroprotective agents in clinical trials
Neurotech Pharmaceuticals developed an intraocular drug delivery system 
using encapsulated cell technology, called NT-501, to consistently release CNTF 
in the vitreous for more than 2 years [93]. A double-masked, randomized, 
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sham-controlled, phase II study enrolling 51 GA patients who were randomly 
divided into 3 groups, high-dose NT-501 implant, low-dose NT-501 implant, and 
sham control group, demonstrated promising outcomes after a 2-year evalu-
ation [94]. Another phase II study using intraocular implant secreting CNTF 
in GA patients has also been completed. In this multicenter, double-masked, 
randomized, sham-controlled, 1-year, dose-ranging phase II study, VA stabiliza-
tion, defined as loss of less than 15 letters, was observed in the high-dose group 
(96.3%) versus low-dose group (83.3%) and sham surgery (75%). All the patients 
with best corrected VA ≥20/63 in the high-dose group lost less than 15 letters, 
while it was only 55.6% in the combined group of patients treated with low-dose 
implant and sham surgery. Additionally, increase of retinal thickness was consis-
tent with the stabilization of VA [95].
Brimonidine, an α-2 agonist, is usually used to treat glaucoma patients in 
ophthalmology. Since brimonidine has been reported to protect neuroretinal cells 
in murine models, the effects of this drug on dry AMD patients were under evalua-
tion [96]. A randomized, double-masked, sham-controlled, phase II study involved 
119 patients with bilateral GA who were randomly divided into 3 groups including 
200 μg treatment, 400 μg treatment, and sham control group. The efficacy and 
safety of brimonidine on biodegradable implant were evaluated after intravitreal 
transplantation [97]. But the results were not reliable, so another multicenter study 
is currently performed with larger samples (311 eyes receiving either treatment 
of 400 μg brimonidine on biodegradable implant or sham treatment) and longer 
evaluation period (up to 24 months) [98].
A retrospective analysis was performed to analyze the association between 
intake of l-DOPA and incidence of AMD. The results showed that the onset of 
AMD in individuals prescribed with l-DOPA was 8 years later when compared with 
those without the uptake of l-DOPA. The protective effects of l-DOPA might be 
through GPR143 (the only known l-DOPA receptor) pathway [99, 100].
There are few studies about exercise as a clinical intervention in AMD, and 
the published papers are observational research showing the correlation between 
exercise and prevalence of AMD. A study lasting for 15 years demonstrated that 
active lifestyle with physical exercise 3 times per week or more was associated with 
reduced risk to develop wet AMD [101]. In another cohort study, an inverse rela-
tion was observed between vigorous exercise (≥3 times/week) and occurrence of 
intermediate AMD in women, not in men [102]. In addition, low physical exercise 
was related to the formation of drusen larger than 63 μm [103].
Electrical neurostimulation has already been applied to patients using less 
invasive approaches, such as transcorneal or whole-eye electrical stimulation, to 
protect the structure and function of retinal neurons. In a clinical trial conducted 
by Anastassiou and colleagues, 22 patients with dry AMD received transpalpebral 
electrical stimulation twice a day for 5 days. Most of the patients demonstrated the 
improvement in VA and contrast sensitivity at 4 weeks after the treatment; how-
ever, only contrast sensitivity was significantly different when compared with sham 
control group [104]. Similarly, microcurrent stimulation (150 μA for 35 min) once 
a week for 3 months was applied to both dry and wet AMD. Significantly increased 
VA was demonstrated in dry AMD, but not in wet AMD. Moreover, the number of 
patients showing increased VA was twice as those exhibiting deterioration [105].
5. Conclusions
AMD is believed to have stronger relationship with age. With increase of 
aging population worldwide, more individuals are suffering from visual damage, 
Neuroprotection
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resulting in poor quality of life for the aged people and elevated cost of medical 
care. In AMD, it is not only the degeneration of RPE cells, but also the neural retina 
degeneration, especially photoreceptors, that leads to the visual impairment. 
Therefore, neuroprotection can be one of the therapeutic strategies to slow, halt, or 
even reverse the progression of retina degeneration. Although the neuroprotective 
interventions that are currently investigated in both animal models and patients 
demonstrate promising results, it is of importance to identify the long-term efficacy 
and safety of these interventions. Only after that, the therapeutics will be provided 
to patients to help them maintain vision and further improve the quality of life.
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